(Q36286346)

13 August 2017

1 reference

title

Concluding remarks: metabolic syndrome, liver and HCV. (English)

1 reference

13 August 2017

1 reference

Cortez-Pinto H

1

1 reference

PubMed ID

16225481

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Alimentary Pharmacology & Therapeutics

13 August 2017

1 reference

13 August 2017

22 Suppl 2

1 reference

13 August 2017

83-85

1 reference

Non-alcoholic fatty liver: another feature of the metabolicsyndrome?

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Liver pathology and the metabolic syndrome X in severe obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

NASH: a hidden and silent fibroser finally revealed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02604.X

10.1111/J.1365-2036.2005.02604.X

21 January 2018

Identifiers

DOI

1 reference

release_xw7hltbzpzen3bgqpefgjgyof4

13 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xw7hltbzpzen3bgqpefgjgyof4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16225481

1 reference

PubMed ID

16225481